gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IMDXHealthcareDiagnostics

Insight Molecular Diagnostics Inc. Common Stock (IMDX)

$2.65−3.28%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$2.86▼ 53.27% in range
Nov 3, 2025Low $2.55 · High $8.48Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Insight Molecular Diagnostics closed at $2.65 on Nov 4, down 3.28%, 68.8% below its 52-week closing high. Volume of 154.1K shares was 0.73× its 20-day average (below normal).

Split-adjusted performance: -21.6% over one month, -47.3% over six months, -56.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $239K, down 53.9% from a year earlier, with a net margin of -4711.3%.

Short interest was 949.5K shares at the Oct 15 settlement, down 2.4% from the prior report (3.7% of float, 3.2 days to cover).

Market cap$86.7M32.7M shares
Revenue · quarter$239.0K−53.9% YoY
Diluted EPS$-0.31—
P/E · TTM—P/S 51.9×
Net margin-4,711.3%Gross 65.7%
Dividend yieldNone
52-week range2.55 – 8.48−68.8% from high
Volume154.1K0.73× 20-day avg
Volatility · 60d94.8%Annualised
Short % of float3.7%3.3 days to cover
Net cash$17.8MCash $17.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −16.7%1M −21.6%3M −44.8%6M −47.3%YTD −64.7%1Y −56.7%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum14
Revenue growth8
Net margin17
Value (low P/E)—
Size29

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short949.5K−2.4% vs prior
Days to cover3.3Settled Oct 15
% of float3.7%
Short vol. 10d52.3%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IMDXInsight Molecular Diagnostics$2.65−3.28%−47.3%−53.9%−4711.3%—$86.7M
ICCCImmucell$10.37+1.17%+19.7%+11.5%25.5%119.6$94.2MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8MCompare
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare
BMRABIOMERICA$1.74+2.06%−21.5%−8.3%−97.4%—$8.0MCompare
QDELQuidelOrtho$14.35+1.85%+30.9%+2.8%−14.7%—$984.1MCompare
VNRXVolitionRx Limited$0.2031+5.23%−91.8%−2.0%−1953.1%—$6.1MCompare
CDIOCardio Diagnostics Holdings$1.65+2.81%−9.6%−28.3%−28012.5%—$4.9MCompare

News about Insight Molecular Diagnostics

All news →
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay PortfolioGlobeNewswire Inc. · Jul 16, 2026▲ Positive

Quick answers

What does Insight Molecular Diagnostics do?
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA).
What is IMDX's market cap?
$86.72M, based on the Nov 4 close of $2.65.
Does Insight Molecular Diagnostics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IMDX is sold short?
949.5K shares, 3.7% of float, as of Oct 15, 2026.
What sector is IMDX in?
Healthcare, in the Diagnostics industry.

About Insight Molecular Diagnostics

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.

HQ: Nashville, TN58 employeesListed Dec 30, 2015imdxinc.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology